Last $1.45 USD
Change Today +0.01 / 0.69%
Volume 5.2K
ENUM On Other Exchanges
As of 5:20 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/14 - $2.25
52 Week Low
04/29/14 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help immune system to attack diseased cells. It focuses on developing a pipeline of product candidates (immunomodulators) for the treatment of cancer and inflammatory diseases. The company was formerly known as Enumeral Biomedical Corp. and changed its name to Enumeral Biomedical Holdings, Inc. in August 2014. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

15 Employees
Last Reported Date: 09/19/14
Founded in 2009

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Total Annual Compensation: $200.0K
Vice President of Business Development and Se...
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Receives Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute to Advance Human Tissue Immuno-Oncology Profiling

Enumeral has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) for $999,967 over two years. The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of the contract. The NCI will be funding the entirety of the program, which will complement Enumeral's other internal research and development efforts. Small volume clinical specimens such as core biopsy or fine needle aspirates often contain limited numbers of cells and can be challenging to analyze with conventional technologies. This Phase II program utilizes Enumeral's platform to obtain multiplexed information from human tissue samples of limited cellularity, potentially addressing these challenges. Enumeral generated proof of concept in this area under a Phase I contract in 2012 and 2013.

Enumeral Appoints Kevin Sarney as Vice President of Finance and Chief Accounting Officer

Enumeral Biomedical Holdings, Inc. announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Prior to joining Enumeral, Mr. Sarney served as Vice President, Finance and Administration at Avaxia Biologics.

Enumeral Biomedical Holdings, Inc. Amends Certificate of Incorporation

Prior to the closing of the Merger, Enumeral Biomedical Holdings, Inc. amended and restated its Certificate of Incorporation. The amendment was approved and adopted by the company's Board of Directors and stockholders. The effective date of the amendment was July 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $1.45 USD +0.01

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 98.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at